Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics.

doi:10.1007/s11926-020-00909-4

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics.

Current rheumatology reports - 16 Jun 2020

Melki Isabelle, Frémond Marie-Louise

Abstract excerpt

PURPOSE OF THE REVIEW: Type I interferonopathies are monogenic autoinflammatory diseases induced by constitutive activation of type I interferon. Here, we provide an overview of these diseases and describe underlying molecular pathways, related phenotypes, suggestive clinical signs and investigations for helping diagnosis process and therapeutic management. RECENT FINDINGS: Recent genetic and functional...

Topics

Autoimmune Diseases
Humans
Interferon Type I
Phenotype
Signal Transduction

Source

Open in PubMed

Identifiers

PMID: 32548765
DOI: 10.1007/s11926-020-00909-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics